SEC Form 4 · accession 0001213900-17-008889
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leonard Sank
Director
Period of report
Aug 15, 2017
Accepted (ET)
Aug 17, 2017 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 15, 2017 | M | 11,262 | $6.00 | A | 282,158 | D | |
| Common StockF1 | holding | — | — | — | 78,125 | I | Via spouse | |
| Common StockF2 | holding | — | — | — | 138,889 | I | Via trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Warrant (right to buy)F3,F4 | $6.00 | Aug 15, 2017 | M | 11,262 | D | Aug 15, 2012 | Aug 15, 2017 | Common Stock | 11,262 | 0 | D |
Explanation of responses
- F1Mr. Sank disclaims beneficial ownership of these shares.
- F2These shares consist of shares of common stock owned by a company wholly owned by a trust of which Mr. Sank is a trustee. Mr. Sank disclaims beneficial ownership of these shares.
- F3The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013.
- F4The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model.